Advancing the Development of Brain-Based Measures of Treatment Outcomes in Clinical Trials across the Lifespan


BrainType: Vanderbilt Reinvestment Award (VRA)

This project aims to advance the development of functional, cost-effective and easy-to-administer brain-based measures of treatment outcomes for use in human clinical trials across the lifespan. Success in translating basic science discoveries to effective treatments or interventions in diverse patient groups depends, in part, on the ability to accurately detect and document the outcomes of clinical trials. The lack of sensitive outcome measures has been recognized as a major barrier to the progress of translational research, especially in vulnerable populations. Another challenge for clinical trials is often the ability to recruit sufficient number of participants, especially for studies involving individuals with rare diseases or with multiple disabilities. The investment into new EEG amplifiers and data processing software will allow the Vanderbilt Kennedy Center (VKC) Psychophysiology Core to address both of these constraints related to human clinical trials across the lifespan.

Faculty Participants

Lead Faculty in bold

Peabody College

School of Medicine (Clinical)

  • Alexandra Key, Research Associate Professor, Dept. of Hearing and Speech Sciences
  • Blythe Corbett, Associate Professor of Psychiatry
  • Paul Newhouse, Professor of Psychiatry, Pharmacology, and Medicine
  • Zach Warren, Associate Professor of Clinical Pediatrics

Related Links